NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $6.80 -0.09 (-1.31%) Closing price 04:00 PM EasternExtended Trading$6.98 +0.19 (+2.72%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About GT Biopharma Stock (NASDAQ:GTBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GT Biopharma alerts:Sign Up Key Stats Today's Range$6.79▼$7.2550-Day Range$5.24▼$11.6352-Week Range$4.91▼$34.25Volume34,331 shsAverage Volume122,400 shsMarket Capitalization$12.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview GT Biopharma, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research centers on its proprietary TriKE (Tandem Trispecific Killer Engager) platform, which is designed to activate natural killer (NK) cells and direct them toward malignant cells while supporting NK-cell expansion and persistence. GT Biopharma has developed investigational product candidates intended to target blood cancers and solid tumors. Its programs have included candidates directed at cancer-associated antigens such as CD33 and CD19, with potential applications in diseases including acute myeloid leukemia and other hematologic malignancies. These therapies remain in development and are not established commercial treatments. The company was formerly known as Oxis International and adopted the GT Biopharma name as it shifted its focus toward immuno-oncology. GT Biopharma is headquartered in the United States and conducts its work through research, clinical development and collaborations related to its NK-cell engager technology.AI Generated. May Contain Errors. Read More GT Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreGTBP MarketRank™: GT Biopharma scored higher than 22% of companies evaluated by MarketBeat, and ranked 806th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGT Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGT Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about GT Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GT Biopharma are expected to grow in the coming year, from ($10.75) to ($8.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GT Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.39% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 1.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently decreased by 93.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.16 News SentimentGT Biopharma has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GT Biopharma this week, compared to 2 articles on an average week.Search Interest8 people have searched for GTBP on MarketBeat in the last 30 days. MarketBeat Follows10 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders1.18% of the stock of GT Biopharma is held by insiders.Percentage Held by Institutions8.15% of the stock of GT Biopharma is held by institutions.Read more about GT Biopharma's insider trading history. Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTBP Stock News HeadlinesGT Biopharma Regains Nasdaq Minimum Bid ComplianceSeptember 27 at 12:44 AM | theglobeandmail.comGT Biopharma Expands Series M Preferred Financing AgreementSeptember 21, 2026 | tipranks.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 28 at 1:00 AM | Behind the Markets (Ad)GT Biopharma consensus price target raised 2,400% to $76.50September 15, 2026 | msn.comGT Biopharma's GTB-5550 Secures FDA IND Clearance For Multiple Myeloma; Stock DownSeptember 15, 2026 | rttnews.comGT Biopharma Announces FDA Clearance of IND for GTB-5550 in Multiple Myeloma and Updates on Phase 1 TrialsSeptember 15, 2026 | quiverquant.comQGT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple MyelomaSeptember 15, 2026 | globenewswire.comGT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy TranscriptSeptember 11, 2026 | seekingalpha.comSee More Headlines GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $19.63 at the beginning of the year. Since then, GTBP stock has decreased by 65.4% and is now trading at $6.80. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Friday, August, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.04. When did GT Biopharma's stock split? GT Biopharma's stock reverse split on Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? Top institutional investors of GT Biopharma include Everhart Financial Group Inc. (0.23%), 49 Wealth Management LLC (0.14%) and 49 Wealth Management LLC (0.14%). View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GT Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today9/28/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, GTBP's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CIK109657 Webwww.gtbiopharma.com Phone(800) 304-9888FaxN/AEmployees8Year Founded1965Profitability EPS (Trailing Twelve Months)($147.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-213.16% Return on Assets-150.61% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.37 per share Price / Cash Flow18.42 Book Value$5.66 per share Price / Book1.20Miscellaneous Outstanding Shares1,804,000Free Float1,783,000Market Cap$12.27 million OptionableNo Data Beta0.91 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:GTBP) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
